0000899243-20-018893.txt : 20200709
0000899243-20-018893.hdr.sgml : 20200709
20200709214637
ACCESSION NUMBER: 0000899243-20-018893
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200707
FILED AS OF DATE: 20200709
DATE AS OF CHANGE: 20200709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zaks Tal Zvi
CENTRAL INDEX KEY: 0001690927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 201021624
MAIL ADDRESS:
STREET 1: 122 BELLEVUE STREET
CITY: NEWTON
STATE: MA
ZIP: 02458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-07
0
0001682852
Moderna, Inc.
MRNA
0001690927
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2020-07-07
4
M
0
22936
12.21
A
22936
D
Common Stock
2020-07-07
4
M
0
24121
19.15
A
47057
D
Common Stock
2020-07-07
4
M
0
15631
19.15
A
62688
D
Common Stock
2020-07-07
4
S
0
23787
58.21
D
38901
D
Common Stock
2020-07-07
4
S
0
17393
58.97
D
21508
D
Common Stock
2020-07-07
4
S
0
7739
60.05
D
13769
D
Common Stock
2020-07-07
4
S
0
13769
60.98
D
0
D
Common Stock
2020-07-08
4
M
0
10000
20.93
A
10000
D
Common Stock
2020-07-08
4
M
0
10000
19.15
A
20000
D
Common Stock
2020-07-08
4
S
0
3238
60.27
D
16762
D
Common Stock
2020-07-08
4
S
0
15619
61.35
D
1143
D
Common Stock
2020-07-08
4
S
0
1143
62.16
D
0
D
Stock Option (Right to Buy)
12.21
2020-07-07
4
M
0
22936
0.00
D
2027-10-03
Common Stock
22936
240824
D
Stock Option (Right to Buy)
19.15
2020-07-07
4
M
0
24121
0.00
D
2026-08-10
Common Stock
24121
260421
D
Stock Option (Right to Buy)
19.15
2020-07-07
4
M
0
15631
0.00
D
2026-08-10
Common Stock
15631
244790
D
Stock Option (Right to Buy)
20.93
2020-07-08
4
M
0
10000
0.00
D
2020-03-08
2029-03-08
Common Stock
10000
329195
D
Stock Option (Right to Buy)
19.15
2020-07-08
4
M
0
10000
0.00
D
2026-08-10
Common Stock
10000
234790
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.57 to $58.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.58 to $59.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.61 to $60.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.63 to $61.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
This option is fully vested and exercisable.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.77 to $60.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.80 to $61.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.94 to $62.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
/s/ Lori Henderson, as Attorney-in-Fact
2020-07-09